Breaks Categories: News

TuesdayOct 28, 2025 1:06 pm

BioMedNewsBreaks — Nutriband Inc. (NASDAQ: NTRB) Receives FDA Meeting Feedback Advancing AVERSA(TM) Fentanyl Toward 505(b)(2) NDA Submission 

Nutriband (NASDAQ: NTRB), a developer of prescription transdermal pharmaceutical products, today announced it has received final meeting minutes from its Sept. 18, 2025, virtual meeting with the U.S. Food and Drug Administration (FDA) regarding its lead product, AVERSA(TM) FENTANYL, an abuse-deterrent fentanyl transdermal system. The meeting with the Division of Anesthesiology, Addiction Medicine, and Pain Medicine confirmed the regulatory pathway as a 505(b)(2) New Drug Application and provided guidance on the reference listed drug and bridging strategy. The FDA also offered feedback on manufacturing validation, product specifications, and stability testing, along with expectations for in vitro manipulation and extraction studies…

Continue Reading

TuesdayOct 28, 2025 12:38 pm

BioMedNewsBreaks — Oncotelic Therapeutics, Inc. (OTCQB: OTLC) Featured in NetworkNewsWire Editorial on Nanomedicine Innovations in Oncology

Oncotelic Therapeutics (OTCQB: OTLC) today announced its inclusion in an editorial published by NetworkNewsWire (“NNW”), one of 70+ brands within the Dynamic Brand Portfolio @ IBN (InvestorBrandNetwork), a communications platform specializing in financial news and content distribution. The article, titled “Nanomedicine Breakthrough Technology Redefining Drug Delivery, Bioavailability in Oncology,” highlights how nanocarrier-based delivery systems are transforming cancer treatment. Oncotelic’s Deciparticle(TM) platform exemplifies this progress by improving bioavailability and therapeutic index across multiple oncology drugs. The advancement of Sapu-003, Intravenous Deciparticle(TM) Everolimus (Afinitor(R)), into human trials underscores the company’s innovation in drug delivery and its mission to enhance efficacy and patient…

Continue Reading

TuesdayOct 28, 2025 11:00 am

BioMedNewsBreaks – Lantern Pharma (NASDAQ: LTRN) Reports Complete Metabolic Response in Phase 1 LP-284 Trial at LL&M Congress

Lantern Pharma (NASDAQ: LTRN), a clinical-stage biopharmaceutical company using its RADR(R) AI platform to transform oncology drug discovery and development, presented clinical data from its ongoing Phase 1 trial of LP-284 at the 25th Annual Lymphoma, Leukemia & Myeloma Congress in New York City, showing a confirmed complete metabolic response in a 41-year-old patient with aggressive Grade 3 non-germinal center B-cell diffuse large B-cell lymphoma after failure of four prior regimens, including CAR-T and bispecific antibody therapies. The response, achieved after two 28-day cycles of LP-284, supports the drug’s synthetic lethal mechanism and potential to fill a critical post-immunotherapy treatment…

Continue Reading

TuesdayOct 28, 2025 10:25 am

BioMedNewsBreaks – HeartBeam Inc. (NASDAQ: BEAT) Partners with HeartNexus to Deliver 24/7 Remote Cardiology Services and Real-Time ECG Interpretation

HeartBeam (NASDAQ: BEAT), a medical technology company focused on transforming cardiac care through personalized insights, today announced a partnership with HeartNexus Inc., a network of board-certified cardiologists specializing in cardiac test interpretation, peer consultations, and telemedicine visits. The collaboration enables HeartBeam to offer 24/7 cardiology reader services for patients experiencing cardiac symptoms outside traditional care settings. Using HeartBeam’s patented 3D technology, patients can capture a 30-second, cable-free ECG recording anytime symptoms occur, transmitting the data to HeartNexus cardiologists for immediate interpretation. “Working with HeartNexus accelerates our mission to make medical-grade cardiac monitoring accessible beyond the walls of a medical facility,”…

Continue Reading

MondayOct 27, 2025 12:01 pm

BioMedNewsBreaks — Nutriband Inc. (NASDAQ: NTRB) Founder Gareth Sheridan Returns as CEO to Lead Final Development Phase of AVERSA Fentanyl 

Nutriband (NASDAQ: NTRB) today announced that company founder Gareth Sheridan has resumed his role as CEO, effective immediately, following a temporary period during which Co-Founder and Chairman Serguei Melnik served in the position. Sheridan will lead the company through its final 2025 development framework toward an expected 2026 NDA filing for AVERSA Fentanyl, the company’s flagship abuse-deterrent opioid patch. AVERSA Fentanyl is designed to deter misuse and accidental exposure, with potential peak annual U.S. sales estimated between $80 million and $200 million. The AVERSA(TM) technology is protected by patents in 46 countries, including the United States, Europe, and Japan. To…

Continue Reading

FridayOct 24, 2025 11:51 am

BioMedNewsBreaks — Nutriband Inc. (NASDAQ: NTRB) Featured in Channelchek Report Highlighting AVERSA Fentanyl Progress

Nutriband (NASDAQ: NTRB), a pharmaceutical company developing transdermal drug delivery technologies, was featured in a Channelchek report by Noble Capital Markets summarizing its presentation at Noble’s Virtual Emerging Growth Conference. The Oct. 23, 2025, report highlights the company’s lead product, AVERSA Fentanyl, an abuse-deterrent transdermal patch that releases aversive agents if tampered with, reducing the risk of opioid misuse. Market projections estimate annual sales of $200 million, potentially rising to $800 million if the FDA mandates abuse-deterrent patches across the category. Following completion of its manufacturing scale-up with Kindeva Drug Delivery, Nutriband expects to begin a human abuse liability study…

Continue Reading

FridayOct 24, 2025 11:40 am

BioMedNewsBreaks – Izotropic Corporation (CSE: IZO) (OTCQB: IZOZF) (FSE: 1R3) Featured in NetworkNewsWire Editorial on AI-Driven Breast Cancer Imaging

Izotropic (CSE: IZO) (OTCQB: IZOZF) (FSE: 1R3) announced its inclusion in a NetworkNewsWire (“NNW”) editorial titled “Investors Turn to AI-Driven Imaging Firms Targeting High-Growth Breast Cancer Market.” The publication explores how artificial intelligence (AI) is reshaping medical imaging, particularly in breast cancer detection, where early and precise diagnosis remains critical to survival rates. Izotropic is highlighted for its IzoView Breast CT Imaging System, a 3D imaging technology designed to improve detection accuracy in women with dense breast tissue. The company’s innovation aligns with rising global demand for advanced diagnostic solutions, as breast cancer remains the most frequently diagnosed cancer among women…

Continue Reading

FridayOct 24, 2025 9:30 am

BioMedNewsBreaks – Lantern Pharma (NASDAQ: LTRN) to Present at ThinkEquity Conference on Oct. 30

Lantern Pharma (NASDAQ: LTRN), an artificial intelligence (AI) company focused on developing cancer therapies and transforming the cost, pace, and timeline of oncology drug discovery, announced that its management team will present at the ThinkEquity Conference on Thursday, Oct. 30, 2025, at 11:30 a.m. ET at the Mandarin Oriental in New York. To view the full press release, visit https://ibn.fm/XaX09 About Lantern Pharma Lantern Pharma (NASDAQ: LTRN) is an AI company transforming the cost, pace, and timeline of oncology drug discovery and development. Our proprietary AI and machine learning (ML) platform, RADR(R), leverages over 200 billion oncology-focused data points and…

Continue Reading

FridayOct 24, 2025 9:20 am

BioMedNewsBreaks – HealthLynked Corp. (OTCQB: HLYK) Launches Upgraded MedOfficeDirect Platform on Shopify

HealthLynked (OTCQB: HLYK), a leading provider of healthcare technology and patient engagement solutions, announced the launch of its new MedOfficeDirect e-commerce platform, now live at DiscountOnlineMedicalSupplies.com and built on Shopify. The upgraded platform delivers faster performance, enhanced security, and a modern checkout experience while offering an average 20% price reduction across its catalog of brand-name medical supplies. HealthLynked plans to expand the curated inventory and, upon completing its marketing and backend transition, migrate the platform back to MedOfficeDirect.com. CEO Dr. Michael Dent said the launch represents a major step forward in accessibility and scalability, enabling patients and healthcare providers to…

Continue Reading

ThursdayOct 23, 2025 12:57 pm

BioMedNewsBreaks — Izotropic Corporation (CSE: IZO) (OTCQB: IZOZF) (FSE: 1R3) CEO Discusses IzoView Commercialization Strategy in New Departures Capital Interview 

Izotropic (CSE: IZO) (OTCQB: IZOZF) (FSE: 1R3), a medical device company developing advanced imaging technologies for the detection and treatment of breast cancer, announced the release of a new video interview with CEO Bob Thast in partnership with Departures Capital. The discussion highlights Izotropic’s vision and near-term strategy for its flagship IzoView breast CT platform, detailing its imaging advantages, patient benefits, and market differentiation. Thast also outlines plans for capital deployment over the next 12–18 months, including production of three IzoView units for an upcoming U.S. FDA clinical study, a partner device in the U.K. to support CE-mark activities, and…

Continue Reading